19227-11-3

Basic information

• Product Name: (1E)-N'-HYDROXY-2-PHENYLETHANIMIDAMIDE
• Synonyms: (1E)-N'-HYDROXY-2-PHENYLETHANIMIDAMIDE;N'-Hydroxy-2-phenylethaneimideamide;PhenylacetaMidoxiMe, 97%;N-hydroxy-2-phenylacetiMidaMide
• CAS NO: 19227-11-3
• Molecular Formula: C₈H₁₀N₂O
• Molecular Weight: 150.18
• Product Categories: Phenyls & Phenyl-Het
• Mol File: 19227-11-3.mol

Chemical Properties

• Melting Point: 66-67℃
• Boiling Point: 335.5 °C at 760 mmHg
• Flash Point: 156.7 °C
• Appearance: /
• Density: 1.14 g/cm³
• CAS DataBase Reference: (1E)-N'-HYDROXY-2-PHENYLETHANIMIDAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: (1E)-N'-HYDROXY-2-PHENYLETHANIMIDAMIDE(19227-11-3)
• EPA Substance Registry System: (1E)-N'-HYDROXY-2-PHENYLETHANIMIDAMIDE(19227-11-3)

Safety Data

• Hazardous Substances Data: 19227-11-3(Hazardous Substances Data)

Usage

Uses

(1E)-N''-Hydroxy-2-phenylethanimidamide

Upstream product

• 140-29-4 phenylacetonitrile 
• 64-17-5 ethanol 
• 7732-18-5 water 
• 7803-49-8 hydroxylamine 
• 342819-31-2 N-benzenesulfonyloxy-2-phenyl-acetamidine 
• 7028-48-0 Phenylacetaldehyde oxime 
• 122-78-1 phenylacetaldehyde 
• 67-56-1 methanol 

Downstream Products

• 878650-03-4 2-[(2-phenyl-acetimidoyl)-aminooxy]-but-2-enedioic acid dimethyl ester 
• 1041005-79-1 3-benzyl-N-cyclohexyl-1,2,4-oxadiazol-5-amine 
• 70541-07-0 N-acetoxy-2-phenyl-acetamidine 
• 53127-68-7 C₁₁H₁₈N₂OSi 
• 519032-07-6 methyl 2-benzyl-5,6-dihydroxypyrimidine-4-carboxylate 
• 844875-63-4 C₃₂H₃₃N₅O₄ 
• 622-77-5 N-benzylcyanamide 
• 55654-03-0 3-benzyl[1.2.4]oxadiazol-5-ylamine 

Relevant articles and documents

Discovery and Structure-Activity-Relationship Study of N-Alkyl-5-hydroxypyrimidinone Carboxamides as Novel Antitubercular Agents Targeting Decaprenylphosphoryl-β-D-ribose 2′-Oxidase

Magnesium plays an important role in infection with Mycobacterium tuberculosis (Mtb) as a signal of the extracellular environment, as a cofactor for many enzymes, and as a structural element in important macromolecules. Raltegravir, an antiretroviral drug

Efficient synthesis of novel 1-hydroxy-2,4,5-trisubstituted imidazole derivatives via a one-pot, four-component reaction between hydroxylamine, benzonitriles, arylglyoxals and cyclic 1,3-dicarbonyl compounds

A simple, and efficient procedure for the synthesis of novel 2,5-diaryl-1-hydroxy-1H-imidazol-4-yl derivatives via a one-pot, four-component reaction between hydroxylamine, benzonitriles, arylglyoxals and cyclic 1,3-dicarbonyl compounds (Melrum’s acid or dimedone) in ethanol under reflux conditions without using bases and catalysts is reported. All the products were obtained in good yields and their structures were established from their spectroscopic data.

Beyond direct Nrf2 activation; reinvestigating 1,2,4-oxadiazole scaffold as a master key unlocking the antioxidant cellular machinery for cancer therapy

Harnessing the antioxidant cellular machinery has sparked considerable interest as an efficient anticancer strategy. Activating Nrf2, the master switch of the cellular redox system, suppresses ROS, alleviates oxidative stress, and halts cancer progression

Synergism of a novel 1,2,4-oxadiazole-containing derivative with oxacillin against methicillin-resistant staphylococcus aureus

Staphylococcus aureus is an important opportunistic pathogen that causes many infections in humans and animals. The inappropriate use of antibiotics has favored the diffusion of methicillin-resistant S. aureus (MRSA), nullifying the efforts undertaken in

Compositions and Methods for the Treatment of Amyotrophic Lateral Sclerosis, Parkinson's Disease, Parkinson's Disease with Dementia, Dementia with Lewy Bodies, and Multiple System Atrophy

The present disclosure provides novel methods for treating or preventing amyotrophic lateral sclerosis (ALS), methods for delaying the onset of neurological symptoms associated with ALS, increasing survival in subjects afflicted with ALS, and attenuating

Synthesis of 2,4-Disubstituted Imidazoles via Nucleophilic Catalysis

A convergent, microwave-assisted protocol for the synthesis of disubstituted NH-imidazoles via nucleophilic catalysis is described. The substituted imidazoles are accessed via the intramolecular addition of a variety of amidoxime substrates to activated a

SO2F2-Mediated one-pot cascade process for transformation of aldehydes (RCHO) to cyanamides (RNHCN)

A simple, mild and practical cascade process for the direct conversion of aldehydes to cyanamides was developed featuring a wide substrate scope and great functional group tolerability. This method allows for transformations of readily available, inexpensive, and abundant aldehydes to highly valuable cyanamides in a pot, atom, and step-economical manner with a green nitrogen source. This protocol will serve as a robust tool for the installation of the cyanamide moiety in various complicated molecules.

Novel phthalide derivatives: Synthesis and anti-inflammatory activity in vitro and in vivo

Phthalide is a promising chemical scaffold and has been proved to show potent anti-inflammatory efficacy. In this study, three series, total of 31 novel phthalide derivatives were designed and synthesized, their anti-inflammatory activities were screened

Investigation around the Oxadiazole Core in the Discovery of a New Chemotype of Potent and Selective FXR Antagonists

Recent findings have shown that Farnesoid X Receptor (FXR) antagonists might be useful in the treatment of cholestasis and related metabolic disorders. In this paper, we report the discovery of a new chemotype of FXR antagonists featured by a 3,5-disubsti

Discovery of BR102375, a new class of non-TZD PPARγ full agonist for the treatment of type 2 diabetes

As a potential treatment of type 2 diabetes, a novel PPARγ non-TZD full agonist, compound 18 (BR102375) was identified from the original lead BR101549 by the SAR efforts of the labile metabolite control through bioisosteres approach. In vitro assessments